Business Of Biotech Biotech Is Back with Allan Shaw
Jan 29, 2024
Renowned biotech CFO, Allan Shaw, shares the reasons behind cautious optimism for biotech's return, including December's M&A activity, interest rate reductions, and easing inflation. They also discuss the election year wildcard and the potential benefits of a metered biotech comeback. The podcast explores topics such as the impact of AI and ML in biotech, the evolution and significance of the JP Morgan conference, and the current state of the industry and innovations.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7
Introduction
00:00 • 2min
Excitement and optimism at the JPM conference with discussion on M&A and IPOs
01:42 • 3min
Feasibility of Forecasted Numbers, FTC's Impact, and the Upcoming Election
05:11 • 3min
Positive Impact of Biotech and Pharma
07:48 • 22min
Exploring the Potential Impact of AI and ML in Biotech
30:14 • 7min
The Evolution and Significance of the JP Morgan Conference
37:16 • 8min
The Current State of the Biotech Industry and Innovations
45:25 • 5min